Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.10
-0.44 (-3.51%)
Nov 21, 2025, 3:04 PM CST
Walvax Biotechnology Company Description
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China.
Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine.
The company was founded in 2001 and is headquartered in Kunming, China.
Walvax Biotechnology Co., Ltd.
| Country | China |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,388 |
| CEO | Wei Yao |
Contact Details
Address: No. 395 Kexin Road Kunming, Yunnan Province 650101 China | |
| Phone | 86 87 1683 30860 |
| Website | walvax.com |
Stock Details
| Ticker Symbol | 300142 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100000WN2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wei Yao | President and Director |
| Shaozhong Dong | Vice Chairman and Vice President |
| Changxiong Wu | Chief Financial Officer |
| Yun Yan Wu | Director of Operations |
| Yu Ran Liu | Board Secretary |
| Qingtang Duan | Engineering Director |